On Jan. 5, NuVasive said it agreed to buy Ellipse in a deal that is expected to be complete by the end of February. NuVasive will pay an additional $30 million in 2017 if Ellipse's portfolio meets certain revenue targets.
"The acquisition fits into NuVasive's portfolio of innovative spinal procedure solutions while also leveraging NuVasive's large sales distribution," said William...





